Drug intelligence / Profile preview

YHC2122

Development stage: Preclinical
Lead developer: Yuhan
Administration: Oral, Injection

Overview

YHC2122 is an early-stage oncology drug candidate being developed by Yuhan Corporation. It is currently in the preclinical phase of development for the treatment of various solid tumors. While Yuhan has categorized YHC2122 as an immuno-oncology (IO) therapeutic, the specific biological target, mechanism of action, and modality (such as a small molecule or monoclonal antibody) have not been publicly disclosed as of 2024. The program represents part of Yuhan's strategic effort to build a robust pipeline of next-generation cancer therapies following the success of its EGFR inhibitor, lazertinib (Leclaza).

Beyond the preview

Go deeper on YHC2122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHC2122.

Explore the full profile